dihexa cancer risk AngIV-Analog Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway dihexa cancer risk hgf c-met
Description
The readout for the phase 3 trial of Ziltivekimab is expected in June 2026 if it works, and if its safe, it could establish IL6 inhibition as a new standard of care for cardiovascular risk reduction in chronic kidney disease
Ready to Get Started?
10.1097/00007632-200102010-00014 18 BaumgartnerL.Wuertz-KozakK.Le MaitreC
Wing RR, Blair EH, Bononi P, Marcus MD, Watanabe R, Bergman RN
Phase 1/2 trial reported no serious adverse events at doses up to 60 mcg/kg (Teichman et al., J Clin Endocrinol Metab 2006)
Rats in both experiments were euthanized in a CO 2 chamber at the end of the experiment
